Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental IL-2 treatment shows promise for Hard-to-Treat HCV vasculitis

NCT ID NCT00574652

Disease control Sponsor: French National Agency for Research on AIDS and Viral Hepatitis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called interleukin-2 (IL-2) in 10 people with hepatitis C-related vasculitis that did not get better with usual treatments. The goal was to see if IL-2 could boost the body's immune regulation and control the disease. Participants received IL-2 injections for several weeks, and researchers monitored immune responses and side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Interleukin-2 (IL-2, also called Proleukin or Aldesleukin)
What this could lead to
If it works, this could point toward a new treatment option for people with HCV-related vasculitis who do not respond to standard therapies.
What could go wrong
This was a very small, early-phase trial with only 10 participants, so results may not apply to everyone. The treatment may not be effective or could cause side effects like vasculitis flares.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

10 people

The number who actually took part.

Start date

Mar 2008

Finished

Sep 2010

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. HCV+ patients with cryoglobulinemia Vasculitis 2. resistant to conventional therapy (i.e. antiviral therapy and/or immunosuppressors). 3. Vasculitis is defined according to international criteria: chronic HCV infection (HCV RNA+), 4. serum cryoglobulin superior or equal to 0.05g/l in at least two determinations, 5. presence of the triad purpura-arthralgia-asthenia and/or biopsy proven Vasculitis (kidney, nerve or skin).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cryoglobulinemia vasculitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cryoglobulinemia Cryoglobulinemic vasculitis vasculitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cryoglobulinemia vasculitis

Contacts and locations

Locations

  • Hôpital de la Pitié

    Paris, 75651, France